10X Genomics, Inc. (TXG)
93.50
+4.74
(+5.34%)
USD |
NASDAQ |
Oct 02, 16:00
94.00
+0.50
(+0.53%)
Pre-Market: 20:00
10X Genomics Gross Profit Margin (Quarterly) : 74.36% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 74.36% |
| March 31, 2026 | 71.09% |
| December 31, 2025 | 69.27% |
| September 30, 2025 | 67.71% |
| June 30, 2025 | 73.53% |
| March 31, 2025 | 70.64% |
| December 31, 2024 | 72.87% |
| September 30, 2024 | 69.50% |
| June 30, 2024 | 69.82% |
| March 31, 2024 | 67.78% |
| December 31, 2023 | 57.65% |
| September 30, 2023 | 56.08% |
| June 30, 2023 | 61.08% |
| March 31, 2023 | 68.44% |
| December 31, 2022 | 72.25% |
| September 30, 2022 | 72.13% |
| June 30, 2022 | 70.16% |
| March 31, 2022 | 77.75% |
| December 31, 2021 | 80.77% |
| Date | Value |
|---|---|
| September 30, 2021 | 75.89% |
| June 30, 2021 | 91.54% |
| March 31, 2021 | 83.88% |
| December 31, 2020 | 83.16% |
| September 30, 2020 | 79.93% |
| June 30, 2020 | 76.57% |
| March 31, 2020 | 78.99% |
| December 31, 2019 | 77.98% |
| September 30, 2019 | 74.71% |
| June 30, 2019 | 73.12% |
| March 31, 2019 | 73.94% |
| December 31, 2018 | 70.53% |
| September 30, 2018 | 85.68% |
| June 30, 2018 | 85.67% |
| March 31, 2018 | 85.52% |
| December 31, 2017 | 84.97% |
| September 30, 2017 | 85.97% |
| June 30, 2017 | 85.83% |
| March 31, 2017 | 83.39% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Twist Bioscience Corp. | 52.76% |
| Tempus AI, Inc. | 63.54% |
| Personalis, Inc. | 21.21% |
| Alamar Biosciences, Inc. (California) | 60.21% |
| Beam Therapeutics, Inc. | -1.00K% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -9.40% |
| Return on Assets | -7.37% |
| Return on Invested Capital | -8.51% |
| Profit Margin (Quarterly) | -11.87% |
| Operating Margin (Quarterly) | -15.20% |
| Return on Net Operating Assets | -16.73% |